Mesa Laboratories, Inc. (NASDAQ: MLAB) (we, us, our, “Mesa” or the “Company”) today announced that it has executed on its previously-announced financial strategy, repaying $97.5 million aggregate ...

“This donation is a small way to express my admiration for Opportunity Project’s work and its impact on so many lives,” said Dr. Saadi. “As a fellow New Jersey organization, we share a deep commitment ...

The Company’s bylaws establish certain procedural requirements and deadlines that are applicable to annual stockholder meetings, including the 2025 Annual Meeting. A copy of the bylaws can be found at ...

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025 La FDA approuve le système Genio® pour le marché américain ; la Société lance la commercialisation du produit ...

Iovance is investigating Amtagvi in frontline advanced melanoma in the Phase 3 trial, TILVANCE-301 (NCT05727904), as well as in additional solid tumor types. About Iovance Biotherapeutics, Inc.

WARREN, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi, has donated 10,000 of his ...

The Company remains on track to initiate the HCW9302 clinical trial in the third quarter of 2025. This trial is a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug ...

Revenue was €1.3 million for the second quarter ending June 30, 2025, compared to €0.8 million for the second quarter ending June 30, 2024, representing a 74% year over year increase. Cost of Goods ...

Photo: Founder and Chief Dentist Dr. Mehmet İşlek of Attelia Dental Clinic receiving the Quality Choice Prize 2025 award.

DALLAS, Aug. 18, 2025 (GLOBE NEWSWIRE) -- BioNTX is pleased to announce the finalists for the Annual Southwest Tech Transfer Showcase, set for Wednesday, September 17th, at the 2025 iC³® Life Science ...

To help close this prevention gap in Florida, a new health platform, WePrevent.org, launched today with a mission to shift ...

Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ...